EICHOR
● Recruiting
A Study to Investigate the Efficacy, Pharmacokinetics, and Safety of Mitapivat in Pediatric Participants With Transfusion-Dependent Alpha- or Beta-Thalassemia (α- or β-TDT)
Condition: Transfusion-dependent Alpha-Thalassemia · Transfusion-dependent Beta-Thalassemia · Sponsor: Agios Pharmaceuticals, Inc.
About this study
The primary objective of this study is to compare the effect of mitapivat versus placebo on transfusion burden in pediatric participants with α- or β-transfusion-dependent thalassemia.
This description comes directly from the study's public registry record.
Talk to the study team
Agios Medical Affairs · 833-228-8474 · medinfo@agios.com
Always discuss trial participation with your own doctor first.
Locations (1)
| University of Texas Southwestern Medical Center | Dallas, Texas, United States | Recruiting |
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07506863